Skip to main navigation Skip to search Skip to main content

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

  • Mary E.R. O'Brien
  • , N. Wigler
  • , M. Inbar
  • , R. Rosso
  • , E. Grischke
  • , A. Santoro
  • , R. Catane
  • , D. G. Kieback
  • , P. Tomczak
  • , S. P. Ackland
  • , F. Orlandi
  • , L. Mellars
  • , L. Alland
  • , C. Tendler
  • Kent Cancer Center
  • Royal Marsden NHS Foundation Trust
  • Tel Aviv Sourasky Medical Center
  • Oncologia Medica I 1st
  • Heidelberg University 
  • IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
  • Shaare Zedek Medical Center
  • Maastricht University
  • Oncology Clinic
  • Hunter Health
  • Hospital Dipreca
  • Merck

Research output: Contribution to journal › Article › peer-review

1670 Scopus citations

Fingerprint

Dive into the research topics of 'Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science